Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Treatment With Evorpacept Combination Initiates in ASPEN-06 Study for Gastric/GEJ Cancer
March 10th 2022Following positive early results from the ASPEN-01 clinical trial, the first patient with HER2-positve gastric or gastroesophageal cancer has received the experimental combination of evorpacept, trastuzumab, ramucirumab, and paclitaxel in ASPEN-06.
Read More
First-Line Nivolumab/Chemotherapy Could Benefit Patients With Gastric/GEJ/Esophageal Cancers
March 6th 2022In an interview with Targeted Oncology, Ryan Sugarman, MD, discussed the CheckMate 649 trial and Q-TWiST results to provide a further understanding of survival and quality of life benefit of nivolumab plus chemo versus chemo alone.
Read More
Pembrolizumab/Chemotherapy Combo Shows Positive Responses in Neoadjuvant Setting of ESCC
February 16th 2022Neoadjuvant treatment with pembrolizumab, paclitaxel, and cisplatin achieved encouraging tumor responses in patients with locally advanced resectable esophageal squamous cell carcinoma.
Read More
Ripretinib Stills Holds a Place in the Advanced GIST Landscape After INTRIGUE Study
January 25th 2022Results presented during the 2022 January ASCO Plenary Series showed that ripretinib did perform better than sunitinib in terms of the objective response rate, and the safety profile of the drug was favorable compared with sunitinib.
Read More
Pembrolizumab Plus Chemotherapy Represents New SOC for Esophageal Cancer/ GEJ Adenocarcinoma
January 22nd 2022According to new KEYNOTE-590 study findings, pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer showed clinical benefit.
Read More